Total endoscopic thyroidectomy.

Hiroshi Takami; Yoshifumi Ikeda

doi:10.1016/s1015-9584(09)60226-8

Home/Archive/PubMed

PubMed · 12732491

Total endoscopic thyroidectomy.

Hiroshi Takami·Yoshifumi Ikeda

View original source ↗Export metadata ↓

Abstract

We have developed endoscopic thyroidectomy procedures using anterior chest and axillary approaches. Both of our procedures differ significantly from the usual thyroidectomy, which involves lifting both the platysma and the sternohyoid muscle. Because only the platysma is lifted during our procedures, a CO(2) insufflation pressure of less than 4 mmHg is sufficient. While the sternohyoid muscle is transected to obtain greater exposure of the thyroid gland in minimally invasive procedures in the neck, we do not divide it so as to prevent adhesions to the platysma, unless the nodule is large. As we accumulated experience with these procedures in 58 patients, typical operation time decreased to less than 120 minutes for the anterior approach and to less than 150 minutes for the axillary approach. Large follicular tumours can be extracted using the axillary approach, with all of its cosmetic advantages, whereas the anterior chest approach is advocated for removal of bilateral multinodular goitres and parathyroid lesions. Both approaches result in minimal postoperative hypoaesthesia, paraesthesia, and discomfort during swallowing. We conclude that endoscopic neck surgery is the procedure of choice in carefully selected patients with thyroid disease.

Explore related subjects

Adenocarcinoma, Follicular Carcinoma, Papillary Endoscopy Female Graves Disease Humans Male Subcutaneous Emphysema Thyroid Neoplasms Thyroidectomy Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Hiroshi Takami, Yoshifumi Ikeda. 2003. Total endoscopic thyroidectomy.. https://doi.org/10.1016/s1015-9584(09)60226-8

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Incidence and survival of Swedish patients with differentiated thyroid cancer.

Papillary (PTC) and follicular (FTC) thyroid cancers are rare disorders but are, nevertheless, among the most common cancers in individuals below 40 years of age. From the population-based Swedish Cancer Registry we identified 3,588 individuals with PTC and 1,966 with FTC during 1958-87. Histopathology was determined by examining the original histopathology reports. The relative survival ratio (RSR) was used as the measure of patient survival. Incidence of both PTC and FTC was higher among women, especially for PTC and particularly during the fertile part of female life. Incidence of PTC increased significantly over time, a trend that was not observed for FTC. Five-year relative survival appeared to be higher for patients diagnosed with PTC compared to FTC, although this difference was almost completely explained by the confounding effect of age. Patients with PTC experience lower mortality during the period 7-20 years after diagnosis. Excess mortality was lower among women, although the magnitude of the difference varied with age and histopathology. In contrast to our perceptions based on clinical practice, we observed no difference in excess mortality between patients diagnosed with PTC and FTC during the years immediately after diagnosis (where the majority of deaths occur). Our data suggest that there may exist a subgroup of thyroid tumors with superior prognosis diagnosed in women during the fertile part of female life. Sex hormones may play a role in the etiology of these tumors.

Adenocarcinoma, Follicular↗

PubMed2003

Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors.

We measured the relative expression levels of galectin-3 mRNA to beta-actin mRNA in normal thyroid tissues, thyroid tumor tissues and thyroid-derived fibroblasts. Galectin-3 mRNA was expressed ubiquitously in both benign and malignant thyroid tumors. Although a significant increase in its expression was observed in papillary carcinomas, no significant difference was observed between follicular carcinomas and adenomas. In contrast to the previous optimistic reports using immunohistochemical analysis of the galectin-3 protein expression, these results demonstrate that galectin-3 mRNA may not be a suitable target for molecular-based diagnosis of thyroid carcinomas.

Adenocarcinoma, Follicular↗

PubMed2003

[Thyroid carcinomas of the follicular epithelium: tumor markers and oncogenes].

Several genes control cell growth, differentiation and apoptosis. Any alteration in the sequence or expression of these genes can cause an uncontrolled growth of the tissue and produce a tumor. Quantitative and qualitative gene expression studies using genes as tumor markers are essential for the diagnosis and prognosis of the tumor and its behavior. Oncogenes are genes that stimulate cell growth and have an increased expression. On the contrary, tumor suppressor genes are genes that inhibit cell growth and have a decreased expression in tumor cells. To study these tumor markers we apply simple and random molecular biology techniques such as polymerase chain reaction (PCR), reverse transcription and genomic sequencing. In the case of thyroid epithelial neoplasia, tumor markers such as PTEN/MMAC1/TEP1, telomerase, RET/PTC, b-catenine, PAX8/PPAR(1, ciclooxygenase, thyroid stimulating hormonal receptor (TSHR), and thyro-globulin are being investigated. These markers are analyzed for somatic mutations in the genetic sequence, chromosomical rearrangements, alterations in the promoter zone that affect gene expression, regulation and studies of genes at mRNA level. A deeper study of these markers is deemed to help improve the accuracy of tumor diagnosis, behavior and prognosis. Hence, more effective therapeutic options will be adapted to each individual, eventually reducing hospital costs.

Adenocarcinoma, Follicular↗